The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

July 08, 2022

John L. Hays, MD, PhD, discusses the importance of genetic testing in colorectal cancer.

June 20, 2022

Nemtabrutinib, a potent, non-covalent BTK inhibitor, continued to demonstrate antitumor activity with an acceptable safety profile in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

May 18, 2022

The FDA has approved pembrolizumab in patients with advanced endometrial cancer that is microsatellite instability-high or mismatch repair–deficient and who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.

April 20, 2022

David P. Carbone, MD, PhD, discusses the evolution of immunotherapy and targeted therapy in non–small cell lung cancer and the importance of biomarker testing for personalized therapy.

March 22, 2022

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has recruited Marcos J. de Lima, MD, to lead its Blood and Marrow Transplant and Cellular Therapy programs, two key leadership positions within central Ohio’s only National Cancer Institute-designated comprehensive cancer center and largest freestanding hospital.

January 31, 2022

Casey M. Cosgrove, MD, discusses utilizing biomarker-informed treatments in endometrial cancer.

January 27, 2022

Casey M. Cosgrove, MD, discussed the current state of biomarkers in the realm of endometrial cancer and how they may be optimally leveraged for prognostic and predictive purposes.

January 17, 2022

Pembrolizumab monotherapy produced meaningful, durable responses in patients with previously treated, advanced microsatellite instability–high or mismatch repair–deficient endometrial cancer.

January 03, 2022

Ashish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.

December 31, 2021

Naresh Bumma, MD, discusses the focus of each presentation on frontline therapy, early and late relapse, and CAR T-cell therapy in multiple myeloma.

November 23, 2021

Ashley E. Rosko, MD, discusses disparities within clinical trials in multiple myeloma.

October 14, 2021

Sameek Roychowdhury, MD, PhD, discusses future research directions with FGFR inhibitors in patients with cholangiocarcinoma.

October 06, 2021

David M. O'Malley, MD, discusses the rationale to evaluate the combination of balstilimab and zalifrelimab in cervical cancer.

September 28, 2021

Germ cell tumors of the ovary are aggressive tumors derived from the primitive germ cells of the embryonic gonad and appear most often in young women or adolescent girls.

September 28, 2021

Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.

September 24, 2021

David M. O'Malley, MD, discusses future research directions with balstilimab and zalifrelimab in patients with cervical cancer.

September 19, 2021

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

September 15, 2021

John C. Byrd, MD, discusses key findings from ELEVATE-RR, differences between acalabrutinib and ibrutinib, and future directions with the second-generation inhibitor.

August 27, 2021

Ibrutinib demonstrated encouraging clinical responses in patients with variant-type, high-risk hairy cell leukemia.

August 16, 2021

David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.